SuperGen Presents Preclinical Data at EORTC On MP-529, a Selective Kinase Inhibitor and CLIMB™ Process in Drug Discovery and Design

SuperGen Presents Preclinical Data at EORTC On MP-529, a Selective Kinase Inhibitor and CLIMB™ Process in Drug Discovery and Design

New anti-cancer drug discovery alliance between GlaxoSmithKline, the Wellcome Trust and The Institute of Cancer Research, focused on B-RAF inhibitors, builds on partnership between Astex, the Wellcome Trust, the Institute of Cancer Research and Cancer Res

New anti-cancer drug discovery alliance between GlaxoSmithKline, the Wellcome Trust and The Institute of Cancer Research, focused on B-RAF inhibitors, builds on partnership between Astex, the Wellcome Trust, the Institute of Cancer Research and Cancer Res